See every side of every news story
Get Started
SubscribeLogin
Ukraine War
Volodymyr Zelenskyy
Donald Trump
Hamas
Israel-Hamas Conflict
Manchester United
Soccer
Vladimir Putin
Elon Musk
Premier League
US Politics
Basketball
Published • loading... • Updated

Welcome Wezlana: Using Adalimumab to Predict Ustekinumab Market Potential

Summary by centerforbiosimilars.com
2025 marks a pivotal year for biosimilars with Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey Poore, MS, of Cardinal Health.
DisclaimerThis story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.

1 Articles

All
Left
Center
Right
centerforbiosimilars.comcenterforbiosimilars.com

Welcome Wezlana: Using Adalimumab to Predict Ustekinumab Market Potential

2025 marks a pivotal year for biosimilars with Amgen's Wezlana leading ustekinumab biosimilar launches, potentially driving savings and access, as highlighted by Dracey Poore, MS, of Cardinal Health.

Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • There is no tracked Bias information for the sources covering this story.
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

centerforbiosimilars.com broke the news in on Monday, February 10, 2025.
Sources are mostly out of (0)
Stories disproportionately reported by the Left or the Right

Similar News Topics

Amgen

Amgen

Mississippi

Mississippi

News
For You
Search
BlindspotLocal